Skip to main content

Bipolar Disorders

Alkermes has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of the investigational drug ALKS 3831, a combination of the antipsychotic olanzapine and samidorphan, a novel molecular entity.
The risk for Parkinson disease appears to be much higher in people with bipolar disorder than in the general population, according to a systematic review and meta-analysis.
SAN DIEGO—Children with bipolar disorder who were treated with lurasidone had a lower risk of all-cause and psychiatric-related hospitalization than those treated with aripiprazole or olanzapine, according to a retrospective claims database study.
SAN DIEGO—Side effects were experienced nearly universally by respondents in an online survey who took oral antipsychotics the previous year for bipolar I disorder, according to results presented at a Psych Congress 2019 poster session.
Increased long-term antibody response to cytomegalovirus and decreased long-term antibody response to Toxoplasma gondii were associated with bipolar disorder as well as the subphenotypes of bipolar I.
Back to Top